Int. J. Mol. Sci. 2013, 14(8), 15878-15884; doi:10.3390/ijms140815878
Editorial

Transparency of Reporting in Molecular Diagnostics

Postgraduate Medical Institute, Anglia Ruskin University, Chelmsford CM1 1SQ, UK
Received: 3 July 2013; in revised form: 23 July 2013 / Accepted: 23 July 2013 / Published: 30 July 2013
(This article belongs to the Section Molecular Diagnostics)
PDF Full-text Download PDF Full-Text [159 KB, uploaded 30 July 2013 16:45 CEST]
Abstract: The major advances made over the past few years in molecular and cell biology are providing a progressively more detailed understanding of the molecular pathways that control normal processes and become dysregulated in disease [1]. This has resulted in the documentation of numerous genetic, epigenetic, transcriptomic, proteomic and metabolomic biomarkers that promise earlier disease detection, more accurate patient stratification and better prognosis [2–5]. Furthermore, molecular fingerprinting of diseases can be predictive of drug response and so assist with specific targeting of drugs against disease-associated molecules and function [6]. [...]

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Bustin, S. Transparency of Reporting in Molecular Diagnostics. Int. J. Mol. Sci. 2013, 14, 15878-15884.

AMA Style

Bustin S. Transparency of Reporting in Molecular Diagnostics. International Journal of Molecular Sciences. 2013; 14(8):15878-15884.

Chicago/Turabian Style

Bustin, Stephen. 2013. "Transparency of Reporting in Molecular Diagnostics." Int. J. Mol. Sci. 14, no. 8: 15878-15884.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert